| Code | CSB-RA859530MB2HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is designed as a research-grade biosimilar to Ponsegromab, targeting growth differentiation factor 15 (GDF15), a stress-responsive cytokine member of the TGF-β superfamily. GDF15 is minimally expressed under physiological conditions but becomes significantly upregulated in response to cellular stress, tissue injury, and inflammation. Elevated GDF15 levels are strongly associated with cancer cachexia, where the cytokine acts on the GFRAL receptor in the brainstem to suppress appetite and induce weight loss. Additionally, GDF15 is implicated in various pathological conditions including cardiovascular disease, metabolic disorders, and pregnancy-related complications such as hyperemesis gravidarum.
Ponsegromab is a humanized IgG4 monoclonal antibody that neutralizes GDF15 and has demonstrated clinical efficacy in treating cancer-associated cachexia by blocking GDF15-GFRAL signaling. This biosimilar antibody provides researchers with a valuable tool for investigating GDF15-mediated pathways, studying cachexia mechanisms, exploring metabolic regulation, and evaluating potential therapeutic interventions in preclinical models of wasting syndromes and metabolic diseases.
There are currently no reviews for this product.